Dassault Systèmes SE Stock
Dassault Systèmes SE Stock
A loss of -1.310% shows a downward development for Dassault Systèmes SE.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Dassault Systèmes SE stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Dassault Systèmes SE in the next few years
Pros
?
B****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Dassault Systèmes SE vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Dassault Systèmes SE | -1.310% | 1.812% | 6.688% | 5.213% | -17.605% | -26.998% | 41.151% |
| Cap Gemini S.A. | -3.640% | 0.360% | 7.227% | 17.001% | 2.657% | 1.351% | 83.279% |
| Akamai Tech. | -0.730% | 1.354% | -2.857% | -10.739% | -17.224% | -4.522% | 10.245% |
| Gartner Inc. | -0.850% | 0.700% | 5.190% | 38.501% | 12.521% | 72.970% | 262.626% |
News
Medidata Recognized as a Leader in Everest Group’s Inaugural Electronic Data Capture PEAK Matrix® Assessment
Medidata, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, has been recognized as a Leader in Everest Group‘s first-ever PEAK Matrix®
EORTC Extends Medidata Partnership to Help Power New Phase of Oncology Research
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and the European Organisation for Research and Treatment of Cancer (EORTC)
Aixial Group Migrates Specific Clinical Data Portfolio Onto Medidata Platform to Create a Single Source of Truth and Accelerate Database Lock
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced a new project with Aixial Group, a contract research organization